DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum depression drug FDA designated a breakthrough therapy in February. Oregon dropped its psilocybin fee hikes, and a GAO audit found DEA and FDA have no written procedures for how scheduling decisions get made.
The post Weekly Psychedelic Policy Briefing: September 30th, 2026 appeared first on Psychedelics Today.
